
Kodiak Sciences (KOD) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
0
Operating Income
-59.1M
Net Income
-57.5M
EPS (Diluted)
$-1.09
Balance Sheet Metrics
Total Assets
297.9M
Total Liabilities
189.1M
Shareholders Equity
108.8M
Debt to Equity
1.74
Cash Flow Metrics
Operating Cash Flow
-34.9M
Free Cash Flow
-29.3M
Revenue & Profitability Trend
Kodiak Sciences Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 126.1M | 206.3M | 267.6M | 217.3M | 107.4M |
Selling, General & Administrative | 60.8M | 71.0M | 73.8M | 49.7M | 28.6M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 186.8M | 277.3M | 341.4M | 267.1M | 136.0M |
Operating Income | -186.8M | -277.3M | -341.4M | -267.1M | -136.0M |
Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | 11.1M | 16.7M | 7.1M | 298.0K | 3.0M |
Interest Expense | 0 | 13.0K | 18.0K | 47.0K | 25.0K |
Other Non-Operating Income | -506.0K | 110.0K | 503.0K | -190.0K | -30.0K |
Pre-tax Income | -176.2M | -260.5M | -333.8M | -267.0M | -133.1M |
Income Tax | - | - | - | - | - |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -176.2M | -260.5M | -333.8M | -267.0M | -133.1M |
Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -149.5M | -234.5M | -322.8M | -258.2M | -128.9M |
EPS (Basic) | - | $-4.97 | $-6.39 | $-5.16 | $-2.91 |
EPS (Diluted) | - | $-4.97 | $-6.39 | $-5.16 | $-2.91 |
Basic Shares Outstanding | - | 52414256 | 52249620 | 51788918 | 45741845 |
Diluted Shares Outstanding | - | 52414256 | 52249620 | 51788918 | 45741845 |
Income Statement Trend
Kodiak Sciences Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 168.1M | 285.5M | 190.4M | 731.5M | 944.4M |
Short-term Investments | - | 0 | 288.5M | 0 | 24.6M |
Accounts Receivable | - | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | 3.9M | 3.8M | 7.1M | 3.3M | 3.0M |
Total Current Assets | 171.9M | 289.3M | 486.0M | 734.8M | 972.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 46.5M | 54.5M | 59.4M | 66.7M | 77.0M |
Goodwill | - | - | - | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 14.9M | 15.0M | 64.9M | 61.3M | 16.5M |
Total Non-Current Assets | 163.6M | 190.1M | 180.6M | 169.4M | 95.3M |
Total Assets | 335.6M | 479.4M | 666.6M | 904.2M | 1.1B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 3.9M | 13.6M | 9.1M | 12.4M | 8.6M |
Short-term Debt | 10.6M | 9.8M | 9.9M | 3.9M | 2.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | -1.0K | - | - |
Total Current Liabilities | 25.6M | 41.7M | 52.5M | 64.7M | 31.4M |
Non-Current Liabilities | |||||
Long-term Debt | 59.7M | 71.9M | 77.8M | 76.1M | 75.0M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 100.0M | 100.0M | 100.2M | 211.0K | 256.0K |
Total Non-Current Liabilities | 159.7M | 171.9M | 178.0M | 176.2M | 175.2M |
Total Liabilities | 185.3M | 213.6M | 230.5M | 240.9M | 206.6M |
Equity | |||||
Common Stock | 5.0K | 5.0K | 5.0K | 5.0K | 5.0K |
Retained Earnings | -1.3B | -1.2B | -892.0M | -558.2M | -291.2M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 150.3M | 265.8M | 436.2M | 663.3M | 860.8M |
Key Metrics | |||||
Total Debt | 70.3M | 81.6M | 87.7M | 80.0M | 77.4M |
Working Capital | 146.4M | 247.6M | 433.5M | 670.1M | 940.6M |
Balance Sheet Composition
Kodiak Sciences Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -176.2M | -260.5M | -333.8M | -267.0M | -133.1M |
Depreciation & Amortization | 26.7M | 25.9M | 11.0M | 8.7M | 4.2M |
Stock-Based Compensation | 60.2M | 88.6M | 106.0M | 61.4M | 30.7M |
Working Capital Changes | -21.0M | -2.9M | 17.0M | 1.2M | 1.4M |
Operating Cash Flow | -109.9M | -148.9M | -200.4M | -195.7M | -96.7M |
Investing Activities | |||||
Capital Expenditures | -400.0K | -41.4M | -47.4M | -63.3M | -7.0M |
Acquisitions | - | - | - | - | - |
Investment Purchases | -355.0K | -49.3M | -427.8M | 0 | -86.3M |
Investment Sales | 0 | 340.0M | 138.6M | 24.5M | 198.1M |
Investing Cash Flow | -755.0K | 249.2M | -336.5M | -38.8M | 104.8M |
Financing Activities | |||||
Share Repurchases | - | - | 0 | 0 | -487.0K |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | 0 |
Debt Repayment | - | - | 0 | 0 | -5.0K |
Financing Cash Flow | - | -211.0K | -49.0K | -45.0K | 711.1M |
Free Cash Flow | -117.7M | -195.6M | -253.8M | -245.6M | -90.4M |
Net Change in Cash | -110.6M | 100.1M | -537.0M | -234.5M | 719.2M |
Cash Flow Trend
Kodiak Sciences Key Financial Ratios
Valuation Ratios
Forward P/E
-2.12
Price to Book
3.90
PEG Ratio
-2.12
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-108.92%
Return on Assets
-34.10%
Financial Health
Current Ratio
4.62
Debt to Equity
62.14
Beta
2.42
Per Share Data
EPS (TTM)
$-3.62
Book Value per Share
$2.07
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
kod | 425.3M | - | 3.90 | -108.92% | 0.00% | 62.14 |
Vertex | 121.3B | 32.82 | 7.05 | 22.77% | 31.86% | 8.89 |
Regeneron | 60.4B | 14.37 | 1.98 | 15.34% | 31.37% | 9.04 |
Harmony Biosciences | 2.0B | 13.13 | 2.74 | 24.71% | 20.50% | 24.63 |
Ocular Therapeutix | 2.0B | - | 7.40 | -57.19% | 91.17% | 28.66 |
Beam Therapeutics | 1.9B | -3.85 | 1.59 | -51.36% | 0.00% | 14.08 |
Financial data is updated regularly. All figures are in the company's reporting currency.